title: In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.
abstract: Burkholderia cepacia complex and Stenotrophomonas maltophilia infections are associated with poor clinical outcomes in persons with cystic fibrosis (CF). The MIC50 based on planktonic growth and the biofilm concentration at which 50% of the isolates tested are inhibited (BIC50) of tobramycin were measured for 180 B. cepacia complex and 101 S. maltophilia CF isolates and were 100 μg/ml for both species. New inhalation devices that deliver high tobramycin levels to the lung may be able to exceed these MICs.
authors.affiliation: Division of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Anina
authors.initials: A
authors.lastname: Ratjen
authors.affiliation: Division of Microbiology, Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Yau
authors.affiliation: Division of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Jillian
authors.initials: J
authors.lastname: Wettlaufer
authors.affiliation: Division of Microbiology, Department of Laboratory Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Larissa
authors.initials: L
authors.lastname: Matukas
authors.affiliation: Division of Infectious Diseases, Department of Pediatrics, Centre for Understanding and Preventing Infection in Children, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: James E A
authors.initials: JE
authors.lastname: Zlosnik
authors.affiliation: Division of Infectious Diseases, Department of Pediatrics, Centre for Understanding and Preventing Infection in Children, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: David P
authors.initials: DP
authors.lastname: Speert
authors.affiliation: Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA.
authors.forename: John J
authors.initials: JJ
authors.lastname: LiPuma
authors.affiliation: Division of Respirology and Keenan Research Centre of Li Ka Shing Knowledge Institute, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Tullis
authors.affiliation: Division of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada valerie.waters@sickkids.ca.
authors.forename: Valerie
authors.initials: V
authors.lastname: Waters
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018441:Biofilms / Q000187:drug effects; D019121:Burkholderia Infections / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology; D042602:Burkholderia cepacia complex / Q000187:drug effects*; D003550:Cystic Fibrosis / Q000150:complications / Q000382:microbiology*; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D020615:Stenotrophomonas maltophilia / Q000187:drug effects*; D014031:Tobramycin / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D014031:Tobramycin